NEW YORK (GenomeWeb News) – BioSeek has extended an agreement with Merck Serono, under which it will continue to profile compounds for the drug developer for another three years, BioSeek said today.
The new agreement extends a previous compound profiling plan from 2008, which had BioSeek using its BioMap platform to evaluate small molecule compounds and proteins in different therapeutic areas. The BioMap Systems use cell-based human disease models to develop information about potential drugs that companies can use to help choose and develop candidates.
The research agreement, which will last until 2012, includes studies that will support target differentiation, lead selection, and nomination of candidates that may be developed by Merck Serono, which is a division of Darmstadt, Germany-based Merck KGaA.
Financial terms of the agreement were not released.